Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E9.45 EPS (ttm)2.21 Insider Own1.40% Shs Outstand294.02M Perf Week-11.33%
Market Cap6.15B Forward P/E15.30 EPS next Y1.37 Insider Trans-26.58% Shs Float289.90M Perf Month-14.27%
Income690.10M PEG0.21 EPS next Q0.27 Inst Own77.40% Short Float6.07% Perf Quarter-8.41%
Sales853.80M P/S7.20 EPS this Y346.30% Inst Trans-0.26% Short Ratio5.11 Perf Half Y23.52%
Book/sh4.31 P/B4.85 EPS next Y31.47% ROA66.80% Target Price31.00 Perf Year-2.43%
Cash/sh2.36 P/C8.86 EPS next 5Y46.00% ROE75.70% 52W Range13.42 - 25.31 Perf YTD6.25%
Dividend- P/FCF16.07 EPS past 5Y29.60% ROI52.60% 52W High-17.42% Beta2.19
Dividend %- Quick Ratio8.40 Sales past 5Y93.70% Gross Margin96.90% 52W Low55.74% ATR0.82
Employees484 Current Ratio8.50 Sales Q/Q90.30% Oper. Margin51.40% RSI (14)29.25 Volatility4.82% 3.27%
OptionableYes Debt/Eq0.00 EPS Q/Q840.80% Profit Margin80.80% Rel Volume1.19 Prev Close21.36
ShortableYes LT Debt/Eq0.00 EarningsMay 14 AMC Payout0.00% Avg Volume3.44M Price20.90
Recom2.10 SMA20-11.83% SMA50-9.53% SMA2003.16% Volume4,100,390 Change-2.15%
Mar-18-19Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-17-18Initiated Goldman Neutral $22
Sep-10-18Initiated Morgan Stanley Underweight $19
May-11-18Reiterated Needham Buy $33 → $30
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-20-19 08:00AM  3 Cancer Treatment Stocks to Buy in April Motley Fool
Apr-19-19 02:12PM  5 Top Pharmaceutical Stocks to Buy in 2019 Motley Fool
12:19PM  5 Top Biotech Stocks to Buy in 2019 Motley Fool
Apr-17-19 04:05PM  Exelixis to Release First Quarter 2019 Financial Results on Wednesday, May 1, 2019 Business Wire -6.52%
Apr-16-19 07:26PM  ProQR Initiates Dosing in Phase II/III Eye Disorder Study Zacks
Apr-15-19 02:18PM  Has Exelixis, Inc. (NASDAQ:EXEL) Got Enough Cash? Simply Wall St.
Apr-11-19 06:33AM  Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock InvestorPlace
Apr-05-19 10:03PM  Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead? Zacks
04:05PM  Exelixis to Present at the 18th Annual Needham Healthcare Conference on April 10, 2019 Business Wire
Apr-01-19 09:25AM  The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage Zacks
Mar-27-19 10:02AM  Market Trends Toward New Normal in 3M, Exelixis, Wright Medical Group N.V, MSA Safety Incorporated, Principal Financial Group, and Portland General Electric Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Mar-18-19 02:26PM  Morgan Stanley Drops Bearish Exelixis Stance, Sees 'Limited Downside Risk' Benzinga
01:06PM  Signal Says Buy Options Insurance on This Biotech Schaeffer's Investment Research
Mar-14-19 05:50PM  Exelixis (EXEL) Gains As Market Dips: What You Should Know Zacks
05:00PM  How a biotech company navigated bay bureaucracy to set up a commuter ferry service American City Business Journals
09:30AM  Why Is Exelixis (EXEL) Up 12.1% Since Last Earnings Report? Zacks
Mar-13-19 05:31PM  5 Biotech Stocks to Keep an Eye on in 2019 GuruFocus.com
01:21PM  Why Exelixis, Inc. (NASDAQ:EXEL) Is An Attractive Investment To Consider Simply Wall St.
Mar-12-19 10:01AM  Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation Zacks
Mar-08-19 05:50PM  Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know Zacks
Mar-05-19 04:05PM  Exelixis Announces Webcasts of Investor Conference Presentations in March Business Wire
07:15AM  3 Best Biotech Bargain Stocks on the Market Right Now Motley Fool
Feb-22-19 04:48PM  Exelixis Inc (EXEL) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Feb-19-19 07:17AM  Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster Motley Fool
Feb-15-19 06:52AM  New Strong Sell Stocks for February 15th Zacks
Feb-14-19 08:40AM  Implied Volatility Surging for Exelixis (EXEL) Stock Options Zacks
Feb-13-19 06:51PM  Cramer's lightning round: These are the two pot stocks I'm recommending CNBC
03:47PM  Exelixis Grabs 90% of First Place Motley Fool
01:25PM  Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4 Zacks
09:35AM  Exelixis Rises as Fourth-Quarter Earnings Beat Estimates TheStreet.com
09:08AM  These 'Small Ball' Names Will Outperform the Market in 2019 TheStreet.com
07:49AM  The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering Benzinga
03:29AM  Edited Transcript of EXEL earnings conference call or presentation 12-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Feb-12-19 11:08PM  Exelixis, Inc (EXEL) Q4 2018 Earnings Conference Call Transcript Motley Fool
05:47PM  Exelixis: 4Q Earnings Snapshot Associated Press
05:20PM  Exelixis (EXEL) Tops Q4 Earnings and Revenue Estimates Zacks
04:06PM  Exelixis Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update Business Wire
04:05PM  Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts Business Wire
03:00PM  Exelixis, Inc. to Host Earnings Call ACCESSWIRE
08:16AM  Q4 Earnings Preview For Exelixis Benzinga
08:04AM  The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares Benzinga
Feb-10-19 05:37PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Feb-07-19 04:31PM  Exelixis (EXEL) to Report Q4 Earnings: What's in Store? Zacks -6.11%
04:05PM  Exelixis to Present at the Guggenheim Healthcare Talks Idea Forum / Oncology Day 2019 on February 14, 2019 Business Wire
Feb-06-19 10:29AM  Heres What Exelixis, Inc.s (NASDAQ:EXEL) P/E Ratio Is Telling Us Simply Wall St.
Feb-05-19 10:30AM  Exelixis (EXEL) Earnings Expected to Grow: Should You Buy? Zacks
Feb-01-19 08:25AM  Factors of Influence in 2019, Key Indicators and Opportunity within Exelixis, Varian Medical, DXC Technology, Bridgepoint Education, Armstrong World Industries, and Immunomedics New Research Emphasizes Economic Growth GlobeNewswire
Jan-29-19 04:05PM  Exelixis to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 12, 2019 Business Wire
Jan-18-19 05:45PM  Exelixis (EXEL) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-17-19 10:18AM  Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod Zacks
Jan-15-19 04:48PM  Heres your guide to the upcoming biotechnology takeover wave MarketWatch +5.21%
09:32AM  How an East Bay cancer fighter once kicked to the curb by Big Pharma picked up its 4th drug approval American City Business Journals
08:49AM  Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer Zacks
07:50AM  Today's Research Reports on Trending Tickers: Exelixis and Editas Medicine ACCESSWIRE
Jan-14-19 06:05PM  5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019 Zacks
05:48PM  Exelixis stock up more than 4% after FDA drug approval MarketWatch
05:38PM  Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma Business Wire
Jan-13-19 03:50PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Jan-11-19 05:45PM  Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know Zacks
12:01PM  How Many Insiders Sold Exelixis, Inc. (NASDAQ:EXEL) Shares? Simply Wall St.
09:04AM  3 Biotech Stocks Bubbling Away Investopedia
Jan-08-19 04:26PM  One Pharma's Approval Just Helped This Highly Rated Biotech Stock Investor's Business Daily +6.30%
09:30AM  Is Exelixis (EXEL) Outperforming Other Medical Stocks This Year? Zacks
06:00AM  Exelixis Collaborator Daiichi Sankyo Receives Regulatory Approval For MINNEBRO (Esaxerenone) Tablets for the Treatment of Hypertension in Japan Business Wire
Jan-04-19 06:04PM  Top 10 Stocks Under $20 Zacks +5.77%
Dec-31-18 07:30AM  Biotech Companies in the News ACCESSWIRE
Dec-27-18 06:21PM  Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure Zacks
Dec-17-18 09:08AM  5 Excellent GARP Picks With Cheap PEG Ratio Zacks
Dec-15-18 08:03AM  3 Biotechs Gilead Sciences Could Buy in March Motley Fool
Dec-14-18 07:59AM  5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride Zacks
Dec-13-18 09:26AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis Zacks
Dec-12-18 10:03AM  Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate Zacks
07:30AM  Report: Developing Opportunities within Exelixis, Cintas, BGC Partners, FirstEnergy, Hologic, and Trevena Future Expectations, Projections Moving into 2018 GlobeNewswire
Dec-11-18 11:59PM  Do Hedge Funds Love Exelixis, Inc. (EXEL)? Insider Monkey
Dec-09-18 04:44PM  Here's Why Exelixis Stock Jumped 46.4% in November Motley Fool
Dec-06-18 09:10AM  Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx Zacks
07:00AM  Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis ACCESSWIRE
Dec-05-18 01:30AM  Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma Business Wire
Dec-04-18 08:39AM  Why Exelixis (EXEL) Could Be Positioned for a Surge Zacks
Dec-03-18 07:00AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Exelixis ACCESSWIRE +5.86%
Dec-01-18 09:31AM  Why Is Exelixis (EXEL) Up 35.9% Since Last Earnings Report? Zacks
Nov-29-18 11:00AM  Biotech's Tackling Major Issues You Should Know ACCESSWIRE
Nov-26-18 03:16PM  Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss Zacks
09:21AM  3 Top Growth Stocks to Buy Right Now Motley Fool
07:55AM  Is Exelixis Incs (NASDAQ:EXEL) CEO Being Overpaid? Simply Wall St.
Nov-23-18 09:03AM  Sarepta Stock More Than Doubles This Year So Far: Here's Why Zacks
Nov-20-18 04:05PM  Exelixis Announces Webcasts of Investor Conference Presentations in November Business Wire
Nov-19-18 10:22AM  Health Care Digest: Chelsea Clinton's shout out, Verily shelves 'smart lens' for diabetes, an East Bay biotech's hunt for employees and more American City Business Journals
Nov-15-18 09:16AM  Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx Zacks
08:10AM  The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results Benzinga
01:32AM  Exelixis Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) Tablets for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib Business Wire
Nov-14-18 11:20AM  Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity ACCESSWIRE
06:55AM  Today's Research Reports on Trending Tickers: Exelixis and Agios Pharmaceuticals ACCESSWIRE
Nov-13-18 03:41PM  Edited Transcript of EXEL earnings conference call or presentation 1-Nov-18 9:00pm GMT Thomson Reuters StreetEvents
Nov-12-18 08:40AM  Detailed Research: Economic Perspectives on Roku, Exelixis, Scientific Games, Boot Barn, Astronics, and AtriCure What Drives Growth in Today's Competitive Landscape GlobeNewswire
07:15AM  Exelixis Revenues for Cabozantinib Continue to Grow, Clinical Development and Regulatory Progress ACCESSWIRE
Nov-08-18 10:20AM  Can Exelixis (EXEL) Run Higher on Rising Earnings Estimates? Zacks
Nov-06-18 04:05PM  Exelixis to Present at the Stifel 2018 Healthcare Conference on November 13, 2018 Business Wire
Nov-05-18 03:22PM  Exelixis Grabs Its Share of the Kidney-Cancer Treatment Market Motley Fool
07:00AM  Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Exelixis ACCESSWIRE
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Invenra, Inc., StemSynergy Therapeutics, Inc., and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MORRISSEY MICHAELPresident and CEOApr 10Option Exercise5.5640,000222,400130,000Apr 12 07:56 PM
MORRISSEY MICHAELPresident and CEOApr 10Sale24.0640,000962,40090,000Apr 12 07:56 PM
Haley Patrick J.Sr. Vice President, CommercialApr 10Sale24.041,00024,04088,780Apr 12 07:59 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 03Option Exercise7.1863,109453,123379,622Apr 03 08:17 PM
SCANGOS GEORGE ADirectorApr 03Sale25.035,000125,1501,273,031Apr 03 08:05 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOApr 03Sale25.0063,1091,577,725316,513Apr 03 08:17 PM
Garber Alan MDirectorApr 01Option Exercise5.2530,000157,35076,329Apr 03 07:58 PM
Hessekiel JeffreyEVP and General CounselApr 01Option Exercise1.7020,00034,000253,820Apr 03 08:01 PM
WYSZOMIERSKI JACK LDirectorApr 01Option Exercise4.3926,250115,350128,031Apr 03 08:09 PM
WYSZOMIERSKI JACK LDirectorApr 01Sale23.977,822187,493120,209Apr 03 08:09 PM
SCANGOS GEORGE ADirectorApr 01Sale24.0240,000960,8001,278,031Apr 03 08:05 PM
Hessekiel JeffreyEVP and General CounselApr 01Sale24.0320,000480,600233,820Apr 03 08:01 PM
Garber Alan MDirectorApr 01Sale23.9930,000719,55061,329Apr 03 07:58 PM
POSTE GEORGEDirectorMar 29Option Exercise4.5715,00068,550106,335Mar 29 07:37 PM
POSTE GEORGEDirectorMar 29Sale23.893,86092,215102,475Mar 29 07:37 PM
MORRISSEY MICHAELPresident and CEOMar 27Option Exercise5.5640,000222,400130,000Mar 29 07:41 PM
MORRISSEY MICHAELPresident and CEOMar 27Sale23.3940,000935,60090,000Mar 29 07:41 PM
Haley Patrick J.Sr. Vice President, CommercialMar 26Option Exercise5.182,70013,98692,480Mar 27 08:31 PM
Haley Patrick J.Sr. Vice President, CommercialMar 26Sale23.472,70063,36989,780Mar 27 08:31 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMar 25Option Exercise7.18100,000718,000416,513Mar 27 08:33 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOMar 25Sale23.14100,0002,314,000316,513Mar 27 08:33 PM
Haley Patrick J.Sr. Vice President, CommercialMar 14Option Exercise1.762,0003,52091,780Mar 15 08:10 PM
SCANGOS GEORGE ADirectorMar 14Sale25.005,000125,0001,318,031Mar 15 08:25 PM
Haley Patrick J.Sr. Vice President, CommercialMar 14Sale25.002,00050,00089,780Mar 15 08:10 PM
MORRISSEY MICHAELPresident and CEOMar 13Option Exercise5.5640,000222,400130,000Mar 15 08:07 PM
MORRISSEY MICHAELPresident and CEOMar 13Sale24.6440,000985,48690,000Mar 15 08:07 PM
Haley Patrick J.Sr. Vice President, CommercialMar 11Sale23.1395922,18289,780Mar 13 08:03 PM
SCANGOS GEORGE ADirectorMar 01Sale22.6640,000906,4001,323,031Mar 01 08:17 PM
MORRISSEY MICHAELPresident and CEOFeb 27Option Exercise5.5640,000222,400130,000Mar 01 08:19 PM
MORRISSEY MICHAELPresident and CEOFeb 27Sale22.6940,000907,60090,000Mar 01 08:19 PM
COHEN CHARLESDirectorFeb 25Option Exercise4.3926,250115,35026,250Feb 27 08:30 PM
Haley Patrick J.Sr. Vice President, CommercialFeb 25Sale22.274,27295,13790,739Feb 27 08:28 PM
COHEN CHARLESDirectorFeb 25Sale22.185,271116,91120,979Feb 27 08:30 PM
MARCHESI VINCENT TDirectorFeb 22Option Exercise4.9541,250204,150175,100Feb 22 07:32 PM
MARCHESI VINCENT TDirectorFeb 22Sale21.5041,250886,875133,850Feb 22 07:32 PM
PAPADOPOULOS STELIOSDirectorFeb 21Option Exercise4.3926,250115,3501,068,501Feb 22 07:35 PM
PAPADOPOULOS STELIOSDirectorFeb 21Sale21.2526,250557,8131,042,251Feb 22 07:35 PM
WILLSEY LANCEDirectorFeb 20Option Exercise4.3926,250115,350444,523Feb 22 07:33 PM
WILLSEY LANCEDirectorFeb 20Sale21.1126,250554,138418,273Feb 22 07:33 PM
COHEN CHARLESDirectorFeb 19Sale21.4848,1801,034,9060Feb 19 08:10 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 15Option Exercise5.5623,000127,880339,513Feb 15 08:11 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 15Sale22.2023,000510,600316,513Feb 15 08:11 PM
COHEN CHARLESDirectorFeb 15Sale22.19100,0002,219,00048,180Feb 19 08:10 PM
FELDBAUM CARL BDirectorFeb 14Option Exercise4.9850,500251,27565,721Feb 15 08:06 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 14Option Exercise5.56100,000556,000416,513Feb 15 08:11 PM
MORRISSEY MICHAELPresident and CEOFeb 14Option Exercise5.5640,000222,400130,000Feb 15 08:14 PM
FELDBAUM CARL BDirectorFeb 14Sale22.0350,5001,112,51515,221Feb 15 08:06 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOFeb 14Sale21.66100,0002,166,000316,513Feb 15 08:11 PM
MORRISSEY MICHAELPresident and CEOFeb 14Sale22.3940,000895,65490,000Feb 15 08:14 PM
COHEN CHARLESDirectorFeb 14Sale22.41100,0002,241,000148,180Feb 19 08:10 PM
Haley Patrick J.Sr. Vice President, CommercialFeb 11Sale21.301,00021,30095,011Feb 13 08:36 PM
SCANGOS GEORGE ADirectorFeb 01Sale23.5340,000941,2001,363,031Feb 01 08:03 PM
MORRISSEY MICHAELPresident and CEOJan 30Option Exercise5.5640,000222,400130,000Feb 01 07:58 PM
MORRISSEY MICHAELPresident and CEOJan 30Sale23.1240,000924,80090,000Feb 01 07:58 PM
MORRISSEY MICHAELPresident and CEOJan 16Option Exercise5.5640,000222,400130,000Jan 18 08:16 PM
MORRISSEY MICHAELPresident and CEOJan 16Sale23.2940,000931,45690,000Jan 18 08:16 PM
Haley Patrick J.Sr. Vice President, CommercialJan 10Option Exercise1.762,0003,52099,011Jan 11 07:56 PM
Haley Patrick J.Sr. Vice President, CommercialJan 10Sale23.853,00071,54096,011Jan 11 07:56 PM
Haley Patrick J.Sr. Vice President, CommercialJan 09Option Exercise5.821,5609,07998,571Jan 09 07:49 PM
Haley Patrick J.Sr. Vice President, CommercialJan 09Sale23.501,56036,66097,011Jan 09 07:49 PM
Garber Alan MDirectorJan 08Option Exercise4.1611,25046,80072,579Jan 09 07:47 PM
Haley Patrick J.Sr. Vice President, CommercialJan 08Option Exercise1.762,0003,52099,011Jan 09 07:49 PM
Haley Patrick J.Sr. Vice President, CommercialJan 08Sale23.002,00046,00097,011Jan 09 07:49 PM
Garber Alan MDirectorJan 08Sale23.0011,250258,75061,329Jan 09 07:47 PM
Haley Patrick J.Sr. Vice President, CommercialJan 07Option Exercise2.905,56016,119101,011Jan 09 07:49 PM
Haley Patrick J.Sr. Vice President, CommercialJan 07Sale21.515,560119,62097,011Jan 09 07:49 PM
MORRISSEY MICHAELPresident and CEOJan 04Option Exercise5.5630,383168,929120,383Jan 04 08:50 PM
MORRISSEY MICHAELPresident and CEOJan 04Sale20.1430,383611,91490,000Jan 04 08:50 PM
Haley Patrick J.Sr. Vice President, CommercialJan 03Option Exercise1.768,00014,080105,011Jan 04 08:15 PM
MORRISSEY MICHAELPresident and CEOJan 03Option Exercise5.563,57119,85593,571Jan 04 08:50 PM
Haley Patrick J.Sr. Vice President, CommercialJan 03Sale19.958,000159,60097,011Jan 04 08:15 PM
SCANGOS GEORGE ADirectorJan 03Sale20.00961,9201,403,031Jan 04 08:18 PM
MORRISSEY MICHAELPresident and CEOJan 03Sale20.003,57171,42090,000Jan 04 08:50 PM
MORRISSEY MICHAELPresident and CEOJan 02Option Exercise5.566,04633,61696,046Jan 04 08:50 PM
SCANGOS GEORGE ADirectorJan 02Sale19.6439,904783,7151,403,127Jan 04 08:18 PM
MORRISSEY MICHAELPresident and CEOJan 02Sale20.006,046120,92090,000Jan 04 08:50 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMODec 03Option Exercise5.0413,49968,035330,012Dec 03 08:00 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMODec 03Sale21.0213,499283,749316,513Dec 03 08:00 PM
SCANGOS GEORGE ADirectorDec 03Sale21.1640,000846,4001,456,981Dec 03 08:03 PM
Senner Christopher J.EVP and CFONov 30Sale19.708,791173,183146,950Nov 30 08:00 PM
SCANGOS GEORGE ADirectorNov 30Sale20.008,500170,0001,496,981Dec 03 08:03 PM
Hessekiel JeffreyEVP and General CounselNov 30Sale19.911,94338,685233,820Nov 30 08:02 PM
SCANGOS GEORGE ADirectorNov 29Sale20.006,500130,0001,505,481Dec 03 08:03 PM
Hessekiel JeffreyEVP and General CounselNov 29Sale19.511,11621,773235,763Nov 30 08:02 PM
Hessekiel JeffreyEVP and General CounselNov 28Sale19.1211,759224,832236,879Nov 30 08:02 PM
MORRISSEY MICHAELPresident and CEONov 15Option Exercise4.4225,000110,500132,647Nov 16 08:22 PM
MORRISSEY MICHAELPresident and CEONov 15Sale17.2225,000430,500107,647Nov 16 08:22 PM
Haley Patrick J.Sr. Vice President, CommercialNov 07Sale17.3220,000346,400104,917Nov 09 07:56 PM
MORRISSEY MICHAELPresident and CEONov 02Option Exercise5.0437,499188,995162,499Nov 02 08:02 PM
MORRISSEY MICHAELPresident and CEONov 02Sale17.5737,499658,964125,000Nov 02 08:02 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMONov 01Option Exercise5.0412,00060,480340,288Nov 02 08:05 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMONov 01Sale14.1612,000169,920328,288Nov 02 08:05 PM
SCANGOS GEORGE ADirectorNov 01Sale14.6625,000366,4001,511,981Nov 02 08:03 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOOct 01Option Exercise5.0412,00060,480340,288Oct 03 08:08 PM
MORRISSEY MICHAELPresident and CEOOct 01Option Exercise5.0412,50163,005137,501Oct 03 08:11 PM
SCANGOS GEORGE ADirectorOct 01Sale17.8625,000446,5001,536,981Oct 03 08:12 PM
MORRISSEY MICHAELPresident and CEOOct 01Sale17.8212,501222,768125,000Oct 03 08:11 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOOct 01Sale17.7712,000213,240328,288Oct 03 08:08 PM
SCANGOS GEORGE ADirectorSep 24Sale16.8525,000421,2501,561,981Sep 26 07:40 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 04Option Exercise5.5022,500123,750350,788Sep 06 08:00 PM